X4 Pharmaceuticals (XFOR) Interest Coverage Ratio (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Interest Coverage Ratio came in at 7.57 in Q2 2026, up 35.55% on a YoY basis from 5.59 in Q2 2025, and up 20.4% quarter-over-quarter from 9.52 in Q1 2026.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported Interest Coverage Ratio for 10 consecutive years, with 7.57 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Coverage Ratio rose 35.55% year-over-year to 7.57; the trailing twelve-month figure through Jun 2026 stood at 10.06 (up 13.09% YoY), and the FY2025 full-year result was 9.79, down 135.78% from the prior year.
- Interest Coverage Ratio improved to 7.57 in Q2 2026 per XFOR's latest filing, from 9.52 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 32.68 in Q2 2024 and bottomed at 26.42 in Q1 2023.
- Historically, Interest Coverage Ratio has averaged 13.33 across 5 years, with a median of 14.9 in 2024.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio surged 245.37% in 2024, then slumped 135.97% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 22.36 in 2022, then surged by 40.24% to 13.36 in 2023, then declined by 16.02% to 15.5 in 2024, then jumped by 30.06% to 10.84 in 2025, then surged by 30.13% to 7.57 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 7.57, 9.52, and 10.84 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -10.28 |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -3.65 |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | -21.24 |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 8.18 |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 1,199.14 |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | -7.57 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.57 |
| Mar 31, 2026 | -9.52 |
| Dec 31, 2025 | -10.84 |
| Sep 30, 2025 | -12.19 |
| Jun 30, 2025 | -11.75 |
| Mar 31, 2025 | -4.29 |
| Dec 31, 2024 | -15.50 |
| Sep 30, 2024 | -14.29 |
| Jun 30, 2024 | 32.68 |
| Mar 31, 2024 | -19.90 |
| Dec 31, 2023 | -13.36 |
| Sep 30, 2023 | -16.65 |
| Jun 30, 2023 | -22.48 |
| Mar 31, 2023 | -26.42 |
| Dec 31, 2022 | -22.36 |
| Sep 30, 2022 | -19.80 |
| Jun 30, 2022 | -22.41 |
| Mar 31, 2022 | -23.29 |
| Dec 31, 2021 | -31.41 |
| Sep 30, 2021 | -20.78 |